Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC.
Federico CarboneStefano MinistriniAldo BonaventuraAlessandra VecchiéSilvia MinettiNicholas BardiEdoardo EliaAnna Maria AnsaldoDaniele FerraraErika RijavecMaria Giovanna Dal BelloFederico BielloGiovanni RossiMarco TagliamentoAngela AlamaSimona CocoPaolo SpallarossaFrancesco GrossiCarlo GenovaFabrizio MontecuccoPublished in: European journal of clinical investigation (2021)
High baseline serum levels of VCAM-1 are associated with a longer survival in patients treated with nivolumab as second line treatment for NSCLC. Surviving patients experience also a significant reduction in CAMs expression during the treatment. Hence, CAMs might be promising prognostic factors in patients with NSCLC underoing immunotherapy.